Clare Arnott1, Christiane Boehm2, Edmund Lau3, David S Celermajer1. 1. Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine, University of Sydney, Camperdown, New South Wales, Australia. 2. Department of Cardiology , Royal Prince Alfred Hospital , Camperdown, New South Wales , Australia. 3. Department of Respiratory , Royal Prince Alfred Hospital , Camperdown, New South Wales , Australia.
Abstract
OBJECTIVE: Since 2006, our institution has cared for 70 patients with pulmonary arterial hypertension (PAH) and severe right ventricular (RV) hypertension; 44 with congenital heart disease (CHD) had Eisenmenger syndrome (ES) and 26 had PAH without CHD. We sought to determine and compare 'real-world' survival outcomes and cause of death in these two distinct groups. METHODS: An observational study of consecutive adult patients from our CHD or PAH clinics with RV systolic pressure ≥80 mm Hg (on echocardiography or right-heart catheter). Detailed patient demographics, investigations and outcomes at baseline and follow-up were reviewed. RESULTS: Patients with ES were younger than non-CHD group (39±9 vs 64±14 years, p<0.001) with a lower proportion of women (61% vs 85%; p=0.04), and higher RV systolic pressure. Estimated 1-year, 3-year and 7-year survival were not significantly different between the groups (98%, 95% and 74% ES; 100%, 92% and 63% non-CHD, p=0.52). In patients with non-CHD, poorer survival was associated with a diagnosis of connective tissue disease (HR 6.90, 95% CI 1.21 to 39.3) and number of PAH therapies (HR 2.8, 95% CI 1.03 to 7.59). Mortality was directly attributed to PAH in 75% of non-CHD group compared with 31% in patients with ES (p=0.049), many of whom died from infection or bleeding. CONCLUSIONS: We report favourable 7-year survival in adults with PAH and systemic RV pressures-equivalent in ES and non-CHD groups. Those with non-CHD predominately died of cardiac complications of PAH, as distinct from those with ES, many of whom died from complications of chronic cyanosis.
OBJECTIVE: Since 2006, our institution has cared for 70 patients with pulmonary arterial hypertension (PAH) and severe right ventricular (RV) hypertension; 44 with congenital heart disease (CHD) had Eisenmenger syndrome (ES) and 26 had PAH without CHD. We sought to determine and compare 'real-world' survival outcomes and cause of death in these two distinct groups. METHODS: An observational study of consecutive adult patients from our CHD or PAH clinics with RV systolic pressure ≥80 mm Hg (on echocardiography or right-heart catheter). Detailed patient demographics, investigations and outcomes at baseline and follow-up were reviewed. RESULTS:Patients with ES were younger than non-CHD group (39±9 vs 64±14 years, p<0.001) with a lower proportion of women (61% vs 85%; p=0.04), and higher RV systolic pressure. Estimated 1-year, 3-year and 7-year survival were not significantly different between the groups (98%, 95% and 74% ES; 100%, 92% and 63% non-CHD, p=0.52). In patients with non-CHD, poorer survival was associated with a diagnosis of connective tissue disease (HR 6.90, 95% CI 1.21 to 39.3) and number of PAH therapies (HR 2.8, 95% CI 1.03 to 7.59). Mortality was directly attributed to PAH in 75% of non-CHD group compared with 31% in patients with ES (p=0.049), many of whom died from infection or bleeding. CONCLUSIONS: We report favourable 7-year survival in adults with PAH and systemic RV pressures-equivalent in ES and non-CHD groups. Those with non-CHD predominately died of cardiac complications of PAH, as distinct from those with ES, many of whom died from complications of chronic cyanosis.
Authors: Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon Journal: Chest Date: 2012-08 Impact factor: 9.410
Authors: Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf Journal: Eur Heart J Date: 2007-01-22 Impact factor: 29.983
Authors: Robyn J Barst; D Dunbar Ivy; Aimee J Foreman; Michael D McGoon; Erika B Rosenzweig Journal: Am J Cardiol Date: 2013-10-04 Impact factor: 2.778
Authors: Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2006-08-03 Impact factor: 21.405
Authors: M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau Journal: Eur Respir J Date: 2010-06-18 Impact factor: 16.671
Authors: Steven M Kawut; Evelyn M Horn; Ketevan K Berekashvili; Robert P Garofano; Rochelle L Goldsmith; Allison C Widlitz; Erika B Rosenzweig; Diane Kerstein; Robyn J Barst Journal: Am J Cardiol Date: 2005-01-15 Impact factor: 2.778
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan Journal: Ann Rheum Dis Date: 2003-11 Impact factor: 19.103